Key statistics
On Monday, Xilio Therapeutics Inc (XLO:NSQ) closed at 0.7558, 54.24% above the 52 week low of 0.49 set on Dec 20, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.8199 |
---|---|
High | 0.82 |
Low | 0.7505 |
Bid | 0.7501 |
Offer | 0.78 |
Previous close | 0.779 |
Average volume | 275.36k |
---|---|
Shares outstanding | 43.95m |
Free float | 32.96m |
P/E (TTM) | -- |
Market cap | 34.24m USD |
EPS (TTM) | -2.11 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 21:00 BST.
More ▼
- Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
- Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
- Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
- Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
- Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
- Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
- Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
- Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
- Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
- Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
More ▼